Drug Profile

VY TAU01

Alternative Names: VY-7523; VY-TAU01

Latest Information Update: 23 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Voyager Therapeutics
Class Antidementias; Gene therapies; Monoclonal antibodies
Mechanism of Action Tau protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Alzheimer's disease

Most Recent Events

31 Dec 2025 Voyager Therapeutics completes enrollment in phase-I clinical trials in Alzheimer's disease (Early-stage disease) (IV) in fourth quarter of 2025
03 Mar 2025 Phase-I clinical trials in Alzheimer's disease (Early-stage disease) (IV)
03 Mar 2025 Pharmacokinetics and adverse events data from a phase Ia trial in Alzheimer's disease released by Voyager Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com